- Abzena and Mabqi have formed a strategic partnership combining antibody discovery with end-to-end biologics development and manufacturing.
- The collaboration aims to streamline workflows, accelerate development timelines, and provide a seamless path from discovery to clinical development.
Abzena, an integrated CDMO specialising in complex biologics and bioconjugates, has announced a strategic partnership with Mabqi, a biotechnology company focused on fully human antibody discovery and development. The collaboration aims to deliver a seamless, end-to-end solution that bridges antibody discovery, development, and GMP manufacturing.
Formed to address the challenges of early-stage drug development, the partnership enables biopharma customers to progress from hit identification through lead selection and pre-clinical development within a single, integrated workflow. Clients will benefit from combined scientific expertise, streamlined processes, and faster timelines.
The alliance will bring together Mabqi’s LiteMab Antibody Discovery Studio—used for hit screening, characterisation, and selection—with Abzena’s expertise in developability assessment, cell line and process development, and GMP manufacturing. Together, the companies can support a wide range of modalities including monoclonal antibodies, fragments, bi- and multi-specifics, and bioconjugates.
“Our partnership with Mabqi brings together two science-rich organisations that are focused on advancing antibody innovation through integration. The combination of our capabilities enables us to significantly accelerate our customers’ discovery programmes from end-to-end by leveraging data to streamline and de-risk earlier on in development.”
Campbell Bunce, Chief Scientific Officer at Abzena
